Umeclidinium bromide

Systematic (IUPAC) name
Diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol bromide
Clinical data
Trade names	Incruse Ellipta
Pregnancy category	US: C (Risk not ruled out)
Legal status	US: ℞-only ℞ (Prescription only)
Routes of administration	Inhalation (DPI)
Pharmacokinetic data
Protein binding	~89%
Metabolism	Hepatic (CYP2D6)
Biological half-life	11 hours
Excretion	Feces (58%) and urine (22%)
Identifiers
CAS Number	869113-09-7
ATC code	R03BB07 (WHO) R03AL03 (+vilanterol)
PubChem	CID: 11519069
ChemSpider	9693857
ChEBI	CHEBI:79040
Synonyms	GSK573719A
Chemical data
Formula	C29H34BrNO2
Molecular mass	508.49 g/mol
SMILES C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5.[Br-]
InChI InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1 Key:PEJHHXHHNGORMP-UHFFFAOYSA-M

Umeclidinium bromide (trade name Incruse Ellipta, GSK) is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol).

External links

• Incruse Ellipta (umeclidinium inhalation powder) Official Site